Anticancer Drugs Compared to No Anticancer Drugs in Patients with Advanced Hepatobiliary Cancer: A Mapping Review and Evidence Gap Map

References

• Surveillance Research Program, National Cancer Institute. SEER*Explorer: an interactive website for SEER cancer statistics [Internet]. In: Surveillance Research Program, National Cancer Institute [Internet]. [cited November 10, 2021]. Available from: https://seer.cancer.gov/explorer/. Accessed November 01, 2023.
   Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Gordan JD, Kennedy EB, Abou-Alfa GK, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline. J Clin Oncol. 2020;38:4317–4345. doi:10.1200/JCO.20.02672
   PubMed Web of Science ®Google Scholar
• Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv238–iv255. doi:10.1093/annonc/mdy308
   PubMed Web of Science ®Google Scholar
• Valle JW, Borbath I, Khan SA, et al. Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v28–v37. doi:10.1093/annonc/mdw324
   PubMed Web of Science ®Google Scholar
• Bracchiglione J, Rodríguez-Grijalva G, Requeijo C, et al. Systemic oncological treatments versus supportive care for patients with advanced Hepatobiliary Cancers: an overview of systematic reviews. Cancers. 2023;15(3):766. doi:10.3390/cancers15030766
   PubMed Web of Science ®Google Scholar
• Corrie PG. Cytotoxic chemotherapy: clinical aspects. Medicine. 2011;39:717–722. doi:10.1016/j.mpmed.2011.09.012
   Google Scholar
• Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ. Aggressiveness of cancer care near the end of life: is it a quality-of-care issue? J Clin Oncol. 2008;26:3860–3866. doi:10.1200/JCO.2007.15.8253
   PubMed Web of Science ®Google Scholar
• Mack JW, Weeks JC, Wright AA, Block SD, Prigerson HG. End-of-life discussions, goal attainment, and distress at the end of life: predictors and outcomes of receipt of care consistent with preferences. J Clin Oncol. 2010;28:1203–1208. doi:10.1200/JCO.2009.25.4672
   PubMed Web of Science ®Google Scholar
• Wasp GT, Knutzen KE, Murray GF, et al. Systemic therapy decision making in advanced cancer: a qualitative analysis of patient-oncologist encounters. JCO Oncol Pract. 2022;18(8):e1357–66.
   PubMedGoogle Scholar
• Vogel A, Bridgewater J, Edeline J, et al. Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:127–140. doi:10.1016/j.annonc.2022.10.506
   PubMed Web of Science ®Google Scholar
• Hui D, De La Cruz M, Mori M, et al. Concepts and definitions for “supportive care,” “best supportive care,” “palliative care,” and “hospice care” in the published literature, dictionaries, and textbooks. Support Care Cancer. 2013;21:659–685. doi:10.1007/s00520-012-1564-y
   PubMed Web of Science ®Google Scholar
• Zafar SY, Currow DC, Cherny N, Strasser F, Fowler R, Abernethy AP. Consensus-based standards for best supportive care in clinical trials in advanced cancer. Lancet Oncol. 2012;13:e77–82. doi:10.1016/S1470-2045(11)70215-7
   PubMed Web of Science ®Google Scholar
• Nipp RD, Currow DC, Cherny NI, Strasser F, Abernethy AP, Zafar SY. Best supportive care in clinical trials: review of the inconsistency in control arm design. Br J Cancer. 2015;113:6–11. doi:10.1038/bjc.2015.192
   PubMed Web of Science ®Google Scholar
• Demols A, Borbath I, Van den Eynde M, et al. Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, Phase II trial. Ann Oncol. 2020;31:1169–1177. doi:10.1016/j.annonc.2020.05.018
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Meyer T, Cheng A-L, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379:54–63. doi:10.1056/NEJMoa1717002
   PubMed Web of Science ®Google Scholar
• Cheng A-L, Kang Y-K, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a Phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34. doi:10.1016/S1470-2045(08)70285-7
   PubMed Web of Science ®Google Scholar
• Bragge P, Clavisi O, Turner T, Tavender E, Collie A, Gruen RL. The global evidence mapping initiative: scoping research in broad topic areas. BMC Med Res Methodol. 2011;11:92. doi:10.1186/1471-2288-11-92
   PubMed Web of Science ®Google Scholar
• Campbell F, Tricco AC, Munn Z, et al. Mapping reviews, scoping reviews, and evidence and gap maps (EGMs): the same but different- The “Big Picture” review family. Syst Rev. 2023;12:45. doi:10.1186/s13643-023-02178-5
   PubMed Web of Science ®Google Scholar
• Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and Explanation. Ann Intern Med. 2018;169:467–473.
   PubMed Web of Science ®Google Scholar
• Pérez-Bracchiglione J, Salazar J, Santero M, et al. Efficacy of systemic oncological treatments in patients with advanced, non-intestinal digestive cancer at high risk of dying in the middle and short term: evidence synthesis. Open Sci Framework. 2022. doi:10.17605/OSF.IO/7CHX6
   Google Scholar
• Methley AM, Campbell S, Chew-Graham C, McNally R, Cheraghi-Sohi S. PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews. BMC Health Serv Res. 2014;14:579. doi:10.1186/s12913-014-0579-0
   PubMed Web of Science ®Google Scholar
• Institute NC, National Cancer Institute. AJCC Cancer Staging Manual 8th Edition. Definitions; 2020. doi:10.32388/b30ldk.
   Google Scholar
• Krnic Martinic M, Pieper D, Glatt A, Puljak L. Definition of a systematic review used in overviews of systematic reviews, meta-epidemiological studies and textbooks. BMC Med Res Methodol. 2019;19:203.
   PubMed Web of Science ®Google Scholar
• Veritas Health Innovation, Melbourne, Australia. Covidence systematic review software. Available from: www.covidence.org. Accessed November 01, 2023.
   Google Scholar
• Haddaway N. Evimappr. In: Evimappr [Internet]; 2020. Available from: https://github.com/nealhaddaway/evimappr. Accessed November 01, 2023.
   Google Scholar
• Chen J, Wang J, Xie F. Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment: a network meta-analysis. Medicine. 2021;100:e27013. doi:10.1097/MD.0000000000027013
   PubMed Web of Science ®Google Scholar
• Ding W, Tan Y, Qian Y, et al. First-line targ veted therapies of advanced hepatocellular carcinoma: a Bayesian network analysis of randomized controlled trials. PLoS One. 2020;15:e0229492. doi:10.1371/journal.pone.0229492
   PubMed Web of Science ®Google Scholar
• Faruque LI, Lin M, Battistella M, et al. Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer. PLoS One. 2014;9:e101145. doi:10.1371/journal.pone.0101145
   PubMed Web of Science ®Google Scholar
• Finn RS, Zhu AX, Farah W, et al. Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: a systematic review and meta-analysis. Hepatology. 2018;67:422–435. doi:10.1002/hep.29486
   PubMed Web of Science ®Google Scholar
• Griffiths CD, Zhang B, Tywonek K, Meyers BM, Serrano PE. Toxicity profiles of systemic therapies for advanced hepatocellular carcinoma: a systematic review and meta-analysis. JAMA Netw Open. 2022;5:e2222721. doi:10.1001/jamanetworkopen.2022.22721
   PubMed Web of Science ®Google Scholar
• Guo T, Liu P, Yang J, et al. Evaluation of targeted agents for advanced and unresectable hepatocellular carcinoma: a network meta-analysis. J Cancer. 2019;10:4671–4678. doi:10.7150/jca.32828
   PubMed Web of Science ®Google Scholar
• Haber PK, Puigvehí M, Castet F, et al. Evidence-based management of Hepatocellular carcinoma: systematic review and meta-analysis of randomized controlled trials (2002–2020). Gastroenterology. 2021;161:879–898. doi:10.1053/j.gastro.2021.06.008
   PubMed Web of Science ®Google Scholar
• Huang Y, Cheng X, Sun P, Li T, Song Z, Zheng Q. Supplementary sorafenib therapies for Hepatocellular Carcinoma-A systematic review and meta-analysis: supplementary sorafenib for liver cancer. J Clin Gastroenterol. 2019;53:486–494. doi:10.1097/MCG.0000000000001175
   PubMed Web of Science ®Google Scholar
• Jácome AA, Castro ACG, Vasconcelos JPS, et al. Efficacy and safety associated with immune checkpoint inhibitors in unresectable Hepatocellular carcinoma: a meta-analysis. JAMA Netw Open. 2021;4:e2136128. doi:10.1001/jamanetworkopen.2021.36128
   PubMed Web of Science ®Google Scholar
• Ling-lin Z, Li M, Jin-hui T, Ke-hu Y. Sorafenib for advanced hepatocellular carcinoma: a systematic review. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2011;33:51–57. doi:10.3881/j.issn.1000-503X.2011.01.011
   PubMedGoogle Scholar
• Liu W, Quan B, Lu S, et al. First-line systemic treatment strategies for unresectable Hepatocellular Carcinoma: a systematic review and network meta-analysis of randomized clinical trials. Front Oncol. 2021;11:771045. doi:10.3389/fonc.2021.771045
   PubMed Web of Science ®Google Scholar
• Meyers BM, Knox JJ, Cosby R, et al. Non-surgical management of advanced hepatocellular carcinoma: a systematic review by Cancer Care Ontario. Can Liver J. 2021;4:257–274. doi:10.3138/canlivj-2020-0039
   PubMedGoogle Scholar
• Niu M, Hong D, T-C M, et al. Short-term and long-term efficacy of 7 targeted therapies for the treatment of advanced hepatocellular carcinoma: a network meta-analysis: efficacy of 7 targeted therapies for AHCC. Medicine. 2016;95:e5591. doi:10.1097/MD.0000000000005591
   PubMed Web of Science ®Google Scholar
• Park R, Lopes da Silva L, Nissaisorakarn V, et al. Comparison of efficacy of systemic therapies in advanced Hepatocellular Carcinoma: updated systematic review and frequentist network meta-analysis of randomized controlled trials. J Hepatocell Carcinoma. 2021;8:145–154. doi:10.2147/JHC.S268305
   PubMed Web of Science ®Google Scholar
• Solimando AG, Susca N, Argentiero A, et al. Second-line treatments for advanced Hepatocellular carcinoma: a systematic review and Bayesian network meta-analysis. Clin Exp Med. 2022;22:65–74. doi:10.1007/s10238-021-00727-7
   PubMed Web of Science ®Google Scholar
• Sonbol MB, Riaz IB, Naqvi SAA, et al. Systemic therapy and sequencing options in advanced Hepatocellular carcinoma: a systematic review and network meta-analysis. JAMA Oncol. 2020;6:e204930. doi:10.1001/jamaoncol.2020.4930
   PubMed Web of Science ®Google Scholar
• Zhang X, Yang X-R, Huang X-W, et al. Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review. Hepatobiliary Pancreat Dis Int. 2012;11:458–466. doi:10.1016/S1499-3872(12)60209-4
   PubMed Web of Science ®Google Scholar
• Abdel Wahab MM, Ezz Elarab LR, Ezz Elarab MA. Capecitabine plus cisplatin treatment in patients with advanced hepatocellular carcinoma. Chin-Ger J Clin Oncol. 2010;9:718–723. doi:10.1007/s10330-010-0698-y
   Google Scholar
• Abou-Alfa GK, Puig O, Daniele B, et al. Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma. J Hepatol. 2016;65:289–295. doi:10.1016/j.jhep.2016.04.004
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Qin S, Ryoo B-Y, et al. Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma. Ann Oncol. 2018;29:1402–1408. doi:10.1093/annonc/mdy101
   PubMed Web of Science ®Google Scholar
• Qin S, Li Q, Gu S, et al. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, Phase 3 trial. Lancet Gastroenterol Hepatol. 2021;6:559–568. doi:10.1016/S2468-1253(21)00109-6
   PubMed Web of Science ®Google Scholar
• Llovet JM, Decaens T, Raoul J-L, et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol. 2013;31:3509–3516. doi:10.1200/JCO.2012.47.3009
   PubMed Web of Science ®Google Scholar
• EudraCT Number 2007-007629-32 - Clinical trial results - EU Clinical Trials Register; [cited June 14, 2023]. Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-007629-32/results. Accessed November 01, 2023.
   Google Scholar
• Zhu AX, Kudo M, Assenat E, et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA. 2014;312:57–67. doi:10.1001/jama.2014.7189
   PubMed Web of Science ®Google Scholar
• Hsu C, Yang T-S, Huo T-I, et al. Vandetanib in patients with inoperable hepatocellular carcinoma: a Phase II, randomized, double-blind, placebo-controlled study. J Hepatol. 2012;56:1097–1103. doi:10.1016/j.jhep.2011.12.013
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Ichida T, Sugitani S, et al. Improved survival with oral administration of enteric-coated tegafur/uracil for advanced stage IV-A hepatocellular carcinoma. J Gastroenterol Hepatol. 2001;16:452–459. doi:10.1046/j.1440-1746.2001.02352.x
   PubMed Web of Science ®Google Scholar
• Kudo M, Morimoto M, Moriguchi M, et al. A randomized, double-blind, placebo-controlled, phase 3 study of tivantinib in Japanese patients with MET-high hepatocellular carcinoma. Cancer Sci. 2020;111:3759–3769. doi:10.1111/cas.14582
   PubMed Web of Science ®Google Scholar
• Ji Y-X, Zhang Z-F, Lan K-T, et al. Sorafenib in liver function impaired advanced hepatocellular carcinoma. Chin Med Sci J. 2014;29:7–14. doi:10.1016/S1001-9294(14)60017-1
   PubMedGoogle Scholar
• Kane RC, Farrell AT, Madabushi R, et al. Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist. 2009;14:95–100. doi:10.1634/theoncologist.2008-0185
   PubMed Web of Science ®Google Scholar
• Kang Y-K, Yau T, Park J-W, et al. Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma. Ann Oncol. 2015;26:2457–2463. doi:10.1093/annonc/mdv388
   PubMed Web of Science ®Google Scholar
• Finn RS, Ryoo B-Y, Merle P, et al. Pembrolizumab as second-line therapy in patients with advanced Hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2020;38:193–202. doi:10.1200/JCO.19.01307
   PubMed Web of Science ®Google Scholar
• Lai CL, Wu PC, Chan GC, Lok AS, Lin HJ. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer. 1988;62:479–483. doi:10.1002/1097-0142(19880801)62:3<479::AID-CNCR2820620306>3.0.CO;2-L
   PubMed Web of Science ®Google Scholar
• Rimassa L, Assenat E, Peck-Radosavljevic M, et al. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncol. 2018;19:682–693. doi:10.1016/S1470-2045(18)30146-3
   PubMed Web of Science ®Google Scholar
• Blanc J-F, Khemissa F, Bronowicki J-P, et al. Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child-Pugh B cirrhosis. Hepatol Int. 2021;15:93–104. doi:10.1007/s12072-020-10120-3
   PubMed Web of Science ®Google Scholar
• Zhu AX, Park JO, Ryoo B-Y, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015;16:859–870. doi:10.1016/S1470-2045(15)00050-9
   PubMed Web of Science ®Google Scholar
• Zhu AX, Kang Y-K, Yen C-J, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:282–296. doi:10.1016/S1470-2045(18)30937-9
   PubMed Web of Science ®Google Scholar
• Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56–66.
   PubMed Web of Science ®Google Scholar
• Rimassa L, Pressiani T, Boni C, et al. A phase II randomized dose escalation trial of sorafenib in patients with advanced hepatocellular carcinoma. Oncologist. 2013;18:379–380. doi:10.1634/theoncologist.2012-0221
   PubMed Web of Science ®Google Scholar
• Kudo M, Moriguchi M, Numata K, et al. S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial. Lancet Gastroenterol Hepatol. 2017;2:407–417. doi:10.1016/S2468-1253(17)30072-9
   PubMed Web of Science ®Google Scholar
• Santoro A, Rimassa L, Borbath I, et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol. 2013;14:55–63. doi:10.1016/S1470-2045(12)70490-4
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390. doi:10.1056/NEJMoa0708857
   PubMed Web of Science ®Google Scholar
• Stemmer SM, Manojlovic NS, Marinca MV, et al. Namodenoson in advanced Hepatocellular carcinoma and Child-Pugh B Cirrhosis: randomized Placebo-Controlled Clinical Trial. Cancers. 2021:13. doi:10.3390/cancers13020187
   PubMedGoogle Scholar
• Daniele B, Di Maio M, Gallo C, et al. A randomized phase III trial comparing sorafenib plus best supportive care (BSC) versus BSC alone in Child-Pugh B patients (pts) with advanced hepatocellular carcinoma (HCC): the BOOST study. J Clin Oncol. 2012;30:TPS4151–TPS4151. doi:10.1200/jco.2012.30.15_suppl.tps4151
   Web of Science ®Google Scholar
• NCT. Sorafenib in liver function impaired advanced Hepatocellular carcinoma; 2013. Available from: https://clinicaltrials.gov/ct2/show/NCT01932385. Accessed November 01, 2023.
   Google Scholar
• Abdelmaksoud AHK, Abdelaziz AO, Nabeel MM, et al. Hepatic arterial infusion chemotherapy in the treatment of advanced hepatocellular carcinoma with portal vein thrombosis: a case-control study. Clin Radiol. 2021;76:709.e1–709.e6. doi:10.1016/j.crad.2021.03.022
   PubMed Web of Science ®Google Scholar
• Chen C-T, Feng Y-H, Yen C-J, et al. Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment. Hepatol Int. 2022;16:1199–1207. doi:10.1007/s12072-022-10392-x
   PubMed Web of Science ®Google Scholar
• Du Y, Yu P, Huang L, Dai G, Cai X. The comparative safety and efficacy of S-1 versus the best supportive care in advanced hepatocellular carcinoma. Int J Clin Exp Med. 2019;12:5412–5418.
   Web of Science ®Google Scholar
• El Baghdady N, Elwakeel L, Ellithy M, Hussein N, Shahin S, El Naggar AR. Efficacy and safety of sorafenib versus supportive care in Egyptian advanced hepatocellular carcinoma patients. Arch Pharm Sci Ain Shams Univ. 2020;4:224–236. doi:10.21608/aps.2020.45180.1043
   Google Scholar
• Hiramine Y, Tamai T, Imamura Y, et al. Efficacy and optimal treatment sequence of Sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. Kanzo. 2013;54:233–248. doi:10.2957/kanzo.54.233
   Google Scholar
• Hiraoka A, Kumada T, Hatanaka T, et al. Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression. Hepatol Res. 2021;51:880–889. doi:10.1111/hepr.13644
   PubMed Web of Science ®Google Scholar
• Hsiao P, Hsieh K-C, Chen Y-S, et al. Sorafenib with concurrent multiple-line therapies improves overall survival in advanced stage hepatocellular carcinoma. Medicine. 2019;98:e16074. doi:10.1097/MD.0000000000016074
   PubMed Web of Science ®Google Scholar
• Jang JW, Bae SH, Choi JY, et al. A combination therapy with transarterial chemo-lipiodolization and systemic chemo-infusion for large extensive hepatocellular carcinoma invading portal vein in comparison with conservative management. Cancer Chemother Pharmacol. 2007;59:9–15. doi:10.1007/s00280-006-0239-0
   PubMed Web of Science ®Google Scholar
• Kang SH, Cho H, Cho EJ, et al. Efficacy of sorafenib for the treatment of post-transplant hepatocellular carcinoma recurrence. J Korean Med Sci. 2018;33:e283. doi:10.3346/jkms.2018.33.e283
   PubMed Web of Science ®Google Scholar
• Lesmana LA, Gani RA, Hasan I, et al. Influence of the sorafenib patients assistance program on treatment compliance and overall survival of unresectable hepatocellular carcinoma patients. Acta Med Indones. 2012;44:228–232.
   PubMedGoogle Scholar
• Sanoff HK, Chang Y, Lund JL, O’Neil BH, Dusetzina SB. Sorafenib effectiveness in advanced Hepatocellular carcinoma. Oncologist. 2016;21:1113–1120. doi:10.1634/theoncologist.2015-0478
   PubMed Web of Science ®Google Scholar
• Trevisani F, Brandi G, Garuti F, et al. Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. J Cancer Res Clin Oncol. 2018;144:403–414. doi:10.1007/s00432-017-2556-6
   PubMed Web of Science ®Google Scholar
• Xia J, Gelfond J, Arora SP. Second-line treatment with nivolumab, cabozantinib, regorafenib, or best supportive care in patients with advanced hepatocellular carcinoma: analysis at a Hispanic-majority NCI-designated cancer center. J Gastrointest Oncol. 2021;12:2943–2951. doi:10.21037/jgo-21-414
   PubMed Web of Science ®Google Scholar
• Zhang Y, Huang G, Miao H, et al. Apatinib treatment may improve survival outcomes of patients with hepatitis B virus-related sorafenib-resistant hepatocellular carcinoma. Ther Adv Med Oncol. 2020;12:1758835920937422. doi:10.1177/1758835920937422
   Web of Science ®Google Scholar
• Abdel-Rahman O, Elsayed Z, Elhalawani H. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas. Cochrane Database Syst Rev. 2018;4:CD011746. doi:10.1002/14651858.CD011746.pub2
   PubMedGoogle Scholar
• Jiang Y, Zeng Z, Zeng J, et al. Efficacy and safety of first-line chemotherapies for patients with advanced biliary tract carcinoma: a systematic review and network meta-analysis. Front Oncol. 2021;11:736113. doi:10.3389/fonc.2021.736113
   PubMedGoogle Scholar
• Lamarca A, Palmer DH, Wasan HS, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021;22:690–701. doi:10.1016/S1470-2045(21)00027-9
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21:796–807. doi:10.1016/S1470-2045(20)30157-1
   PubMed Web of Science ®Google Scholar
• Glimelius B, Hoffman K, Sjödén PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol. 1996;7:593–600. doi:10.1093/oxfordjournals.annonc.a010676
   PubMed Web of Science ®Google Scholar
• Kataria B, Sharma A, Mishra S, et al. Capecitabine +best supportive care (BSC) or erlotinib +BSC has overall survival (OS) benefit over BSC alone in unresectable/metastatic gall bladder cancer (GBC) patients with ECOG PS-III. Results from a phase II randomised controlled trial (RCT). Ann Oncol. 2019;30:v279. doi:10.1093/annonc/mdz247.052
   Web of Science ®Google Scholar
• Park DH, Lee SS, Park SE, et al. Randomised phase II trial of photodynamic therapy plus oral fluoropyrimidine, S-1, versus photodynamic therapy alone for unresectable hilar cholangiocarcinoma. Eur J Cancer. 2014;50:1259–1268. doi:10.1016/j.ejca.2014.01.008
   PubMed Web of Science ®Google Scholar
• Sharma A, Dwary AD, Mohanti BK, et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol. 2010;28:4581–4586. doi:10.1200/JCO.2010.29.3605
   PubMed Web of Science ®Google Scholar
• Takada T, Nimura Y, Katoh H, et al. Prospective randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C for non-resectable pancreatic and biliary carcinoma: multicenter randomized trial. Hepato-gastroenterology. 1998;45:2020–2026.
   PubMedGoogle Scholar
• Duan H. An open-label controlled clinical trial of apatinib in the treatment of advanced biliary tract cancer; 2017. Report No.: ChiCTR-IIR-17014202. Available from: https://trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR-IIR-17014202. Accessed November 01, 2023.
   Google Scholar
• Singh SK, Talwar R, Kannan N, Tyagi AK, Jaiswal P, Kumar A. Chemotherapy compared with best supportive care for metastatic/unresectable gallbladder cancer: a non-randomized prospective cohort study. Indian J Surg Oncol. 2016;7:25–31. doi:10.1007/s13193-015-0443-7
   PubMed Web of Science ®Google Scholar
• Azarfane M, Lièvre A, Senellart H, et al. Predictive factors of chemotherapy initiation after biliary drainage for advanced biliary tract cancer: a retrospective multicenter study. J Gastrointestin Liver Dis. 2021;30:254–258. doi:10.15403/jgld-3120
   PubMed Web of Science ®Google Scholar
• Brunner TB, Schwab D, Meyer T, Sauer R. Chemoradiation may prolong survival of patients with non-bulky unresectable extrahepatic biliary carcinoma. A retrospective analysis. Strahlenther Onkol. 2004;180:751–757. doi:10.1007/s00066-004-1315-1
   PubMed Web of Science ®Google Scholar
• Dierks J, Gaspersz MP, Belkouz A, et al. Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin. Acta Oncol. 2018;57:807–812. doi:10.1080/0284186X.2017.1418532
   PubMed Web of Science ®Google Scholar
• Dover LL, McDonald AM, Derek DA, Wang TN, Oster RA, Jacob R. Impact of definitive chemoradiation therapy on survival in patients with unresectable cholangiocarcinoma. Int J Radiat Oncol Biol Phys. 2014;90:S204. doi:10.1016/j.ijrobp.2014.05.759
   Web of Science ®Google Scholar
• Ghiassi-Nejad Z, Moshier E, Schwartz M, Buckstein M. Definitive chemoradiation therapy in the treatment of unresectable intrahepatic cholangiocarcinoma: a national cancer data base study. Int J Radiat Oncol Biol Phys. 2016;96:E211–E212. doi:10.1016/j.ijrobp.2016.06.1122
   Web of Science ®Google Scholar
• Ishii H, Furuse J, Yonemoto N, Nagase M, Yoshino M, Sato T. Chemotherapy in the treatment of advanced gallbladder cancer. Oncology. 2004;66:138–142. doi:10.1159/000077440
   PubMed Web of Science ®Google Scholar
• Ji JH, Kim YS, Park I, et al. Chemotherapy versus best supportive care in advanced biliary tract carcinoma: a multi-institutional propensity score matching analysis. Cancer Res Treat. 2018;50:791–800. doi:10.4143/crt.2017.044
   PubMed Web of Science ®Google Scholar
• Koch C, Franzke C, Bechstein WO, et al. Poor prognosis of advanced cholangiocarcinoma: real-world data from a tertiary referral center. Digestion. 2020;101:458–465. doi:10.1159/000500894
   PubMed Web of Science ®Google Scholar
• Mao W, Deng F, Wang D, Gao L, Shi X. Treatment of advanced gallbladder cancer: a SEER-based study. Cancer Med. 2020;9:141–150. doi:10.1002/cam4.2679
   PubMed Web of Science ®Google Scholar
• Min Jae K, Hwang J-H, Lee J-C, Shin DW, Yang SY. Impact on gemcitabine plus cisplatin in unresectable hilar cholangiocarcinoma patients according to effective bile drainage. Ann Oncol. 2018;29 Suppl 9:ix50. doi:10.1093/annonc/mdy432.010
   Web of Science ®Google Scholar
• Moik F, Riedl JM, Winder T, et al. Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: a propensity score analysis. Sci Rep. 2019;9:5548. doi:10.1038/s41598-019-42069-1
   PubMed Web of Science ®Google Scholar
• Shin DW, Kim MJ, Lee J-C, et al. Gemcitabine plus cisplatin chemotherapy prolongs the survival in advanced Hilar cholangiocarcinoma: a large multicenter study. Am J Clin Oncol. 2020;43:422–427. doi:10.1097/COC.0000000000000682
   PubMed Web of Science ®Google Scholar
• Singh P, Sharma S, Kapoor R, et al. Best supportive care compared with chemotherapy and radiotherapy for unresectable gallbladder cancer: a tertiary care institute experience. Clin Cancer Investig J. 2014;3:153. doi:10.4103/2278-0513.130214
   Google Scholar
• Yonemoto N, Furuse J, Okusaka T, et al. A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Jpn J Clin Oncol. 2007;37:843–851. doi:10.1093/jjco/hym116
   PubMed Web of Science ®Google Scholar
• Zaidi A, Chandna N, Narasimhan G, et al. Second-line chemotherapy prolongs survival in real world patients with advanced biliary tract and gallbladder cancers: a multicenter retrospective population-based cohort study. Am J Clin Oncol. 2021;44:93–98. doi:10.1097/COC.0000000000000789
   PubMed Web of Science ®Google Scholar
• Ganz PA. Delivering patient-centered care in the setting of advanced cancer: what does a clinical risk-prediction model have to do with It? JAMA Oncol. 2015;1(4):430–432. doi:10.1001/jamaoncol.2015.0832
   PubMed Web of Science ®Google Scholar
• Balogh EP, Ganz PA, Murphy SB, Nass SJ, Ferrell BR, Stovall E. Patient-centered cancer treatment planning: improving the quality of oncology care. Summary of an Institute of Medicine workshop. Oncologist. 2011;16:1800–1805. doi:10.1634/theoncologist.2011-0252
   PubMed Web of Science ®Google Scholar
• Williamson PR, Altman DG, Bagley H, et al. The COMET Handbook: version 1.0. Trials. 2017;18:280. doi:10.1186/s13063-017-1978-4
   PubMed Web of Science ®Google Scholar
• Prinsen CAC, Vohra S, Rose MR, et al. How to select outcome measurement instruments for outcomes included in a “Core Outcome Set” - a practical guideline. Trials. 2016;17:449. doi:10.1186/s13063-016-1555-2
   PubMed Web of Science ®Google Scholar
• Evans CJ, Benalia H, Preston NJ, et al. The selection and use of outcome measures in palliative and end-of-life care research: the MORECare International Consensus Workshop. J Pain Symptom Manage. 2013;46(6):925–937. doi:10.1016/j.jpainsymman.2013.01.010
   PubMed Web of Science ®Google Scholar
• Ramsey I, Eckert M, Hutchinson AD, Marker J, Corsini N. Core outcome sets in cancer and their approaches to identifying and selecting patient-reported outcome measures: a systematic review. J Patient Rep Outcomes. 2020;4:77. doi:10.1186/s41687-020-00244-3
   PubMedGoogle Scholar
• Bouça-Machado R, Rosário M, Alarcão J, Correia-Guedes L, Abreu D, Ferreira JJ. Clinical trials in palliative care: a systematic review of their methodological characteristics and of the quality of their reporting. BMC Palliat Care. 2017;16:10. doi:10.1186/s12904-016-0181-9
   PubMed Web of Science ®Google Scholar
• Zambrano SC, Haugen DF, van der Heide A, et al. Development of an international Core Outcome Set (COS) for best care for the dying person: study protocol. BMC Palliat Care. 2020;19:184. doi:10.1186/s12904-020-00654-6
   PubMed Web of Science ®Google Scholar